BEIJING - THEY are paralysed from diving accidents and car crashes, disabled by Parkinson's, or blind.
With few options available at home in America, they search the Internet for experimental treatments - and often land on websites promoting stem cell treatments in China.
They mortgage their houses and their home towns hold fund-raisers as they scrape together the tens of thousands of dollars needed for travel and the hope for a miracle cure.
A number of these medical tourists claim some success when they return home:
Link to Article
ASIAONE.com
|
|
||||
|
This Month
Month Archive
RSS Newsfeeds
Main Page RSS
|
Friday, January 4
Americans seek stem cell miracles in China
by
Alex Hsieh on behalf of Professor Henry Wang
on Fri 04 Jan 2008 11:24 PM EST
Global pharma
by
Alex Hsieh on behalf of Professor Henry Wang
on Fri 04 Jan 2008 11:22 PM EST
With investors preparing for a downturn, defensive stocks are shooting through the roof. But there is an exception: pharmaceuticals. The sector remains mired by structural problems, mainly blockbuster drugs that will go off patent in the next few years, falling research & development productivity, and pricing pressure, especially in the US. The question for investors is whether they can pick out the coming success stories amid the general malaise.
Link to Article FT.com
FDA Funding Increases in FY 2008
by
Lyle
on Fri 04 Jan 2008 05:57 PM EST
GEN News Highlights - 1/4/08
by
Lyle
on Fri 04 Jan 2008 05:55 PM EST
Link to All Articles
Jan 03 2008, 12:18 PM EST BioFocus Inks Target Discovery Agreement in Oncology with Janssen Worth about $15.5M Transaction includes $4.27 million upfront for assay development, adenoviral library screening, and target validation. Full Story Jan 03 2008, 12:22 PM EST A Glitch in Cells' Recycling Process Found to Trigger Parkinson's Paper in The Journal of Clinical Investigation describes how modified alpha-synuclein disrupts autophagy, which may cause death of dopamine-producing nerve cells. Full Story Jan 03 2008, 12:29 PM EST Merck & Co. Agrees to Pay up to $702M for Addex' Schizophrenia Compounds Company will initially put down $22 million in this two-product collaboration. Full Story Jan 03 2008, 12:28 PM EST Third Mechanism for Activating Ion Channels Identified Thioredoxin donates electrons to unlock ion channels, according to a study published in Nature. Full Story Jan 02 2008, 11:12 AM EST Merck & Co. Sells Manufacturing Facility to PRWT Supply deal also inked, which could earn PRWT between $100-200 million annually. Full Story Jan 02 2008, 11:18 AM EST Sepracor In-Licenses Phase III Epilepsy Drug from Bial for $75M Upfront Transaction covers development and commercialization in the U.S. and Canada with milestone fees totaling $100 million. Full Story Dec 28 2007, 11:45 AM EST Systems Biology Approach Predicts Molecular Response of Living Cells to Genetic or Environmental Change A Cell paper describes the EGRIN model, which used Halobacterium salinarum NRC-1. Full Story Dec 28 2007, 11:33 AM EST Millennium to Receive $40M for Achieving Sales Milestone with Velcade Fee is part of a 2003 deal between the company and Ortho Biotech Products. Full Story GenEngNews.com
FDA Panel Rejects OTC Status for Merck’s “Mevacor”
by
Lyle
on Fri 04 Jan 2008 05:51 PM EST
GEN News Highlights - 12/28/07
by
Lyle
on Fri 04 Jan 2008 05:48 PM EST
Link to All Articles
Dec 27 2007, 12:06 PM EST Source MDx Inks Translational Medicine Deal with Pfizer Biomarkers will be developed to advance Pfizer's cancer and inflammation pipelines with the potential to jointly commercialize companion diagnostics. Full Story Dec 27 2007, 12:05 PM EST Researchers Ascertain Genes that Can Arrest Development of Regulatory T Cells GATA-2 blocks FOXP3, suppressing the production of these T cells, which help people avoid allergic reactions, according to study in PLoS Biology. Full Story Dec 27 2007, 12:08 PM EST Protein Identified that Promotes Cancer Cell Survival under Hypoxic Stress Molecular Cell paper provides evidence that FOXO3a triggers transcription of HIF1 target gene, which in turn inhibits HIF-1 induced apoptosis. Full Story Dec 26 2007, 11:37 AM EST Cubist Purchases Illumigen for $9M Illumigen shareholders could earn up to $332.5 million in milestone-dependent fees. Full Story Dec 21 2007, 12:38 PM EST Merck & Co. Gets the Green Light for HIV Treatment in EU Isentress, which represents the first integrase inhibitor, will be marketed in all member states, and the firm will receive licenses for Norway and Iceland. Full Story Dec 21 2007, 12:57 PM EST FDA Finds Satisfactory Resolution of Akorn cGMP Issues Decision covers Decatur, IL facility. Full Story Dec 21 2007, 12:34 PM EST Presidio Reneges on Part of $75.25M HIV Drug Agreement with Medivir Newly available rights for MIV-310 picked up by Beijing Mefuvir Medicinal Technology. Full Story GenEngNews.com |
Search
Links
|
||